(NASDAQ: HUMA) Humacyte's forecast annual revenue growth rate of 278.13% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 97.96%, and it is also forecast to beat the US market's average forecast revenue growth rate of 25.83%.
Humacyte's revenue in 2025 is $1,571,000.On average, 9 Wall Street analysts forecast HUMA's revenue for 2025 to be $565,372,118, with the lowest HUMA revenue forecast at $480,538,210, and the highest HUMA revenue forecast at $723,616,384. On average, 9 Wall Street analysts forecast HUMA's revenue for 2026 to be $4,517,171,534, with the lowest HUMA revenue forecast at $2,024,028,437, and the highest HUMA revenue forecast at $8,775,908,645.
In 2027, HUMA is forecast to generate $17,579,533,445 in revenue, with the lowest revenue forecast at $9,359,820,624 and the highest revenue forecast at $30,124,464,696.